share_log

Bristol-Myers Squibb | 8-K: Bristol-Myers Squibb Announces Completion of Acquisition of Karuna Therapeutics

Bristol-Myers Squibb | 8-K: Bristol-Myers Squibb Announces Completion of Acquisition of Karuna Therapeutics

施貴寶 | 8-K：施貴寶宣佈完成對Karuna Therapeutics的收購
SEC announcement ·  03/18 20:59
牛牛AI助理已提取核心訊息
On March 18, 2024, Bristol-Myers Squibb (BMS) announced the successful completion of its acquisition of Karuna Therapeutics, Inc., a move that strengthens BMS's neuroscience portfolio. The acquisition results in Karuna becoming a wholly owned subsidiary of BMS, with Karuna's common stock ceasing to trade on the Nasdaq. The transaction involved the conversion of each Karuna share into the right to receive $330.00 in cash. BMS's acquisition includes KarXT, a potential first-in-class schizophrenia treatment with a PDUFA date set for September 26, 2024, and a pipeline of early-stage and pre-clinical neuroscience assets. The acquisition is expected to be dilutive to BMS's non-GAAP diluted earnings per share by approximately $0.30 in 2024 due to financing costs, but BMS plans...Show More
On March 18, 2024, Bristol-Myers Squibb (BMS) announced the successful completion of its acquisition of Karuna Therapeutics, Inc., a move that strengthens BMS's neuroscience portfolio. The acquisition results in Karuna becoming a wholly owned subsidiary of BMS, with Karuna's common stock ceasing to trade on the Nasdaq. The transaction involved the conversion of each Karuna share into the right to receive $330.00 in cash. BMS's acquisition includes KarXT, a potential first-in-class schizophrenia treatment with a PDUFA date set for September 26, 2024, and a pipeline of early-stage and pre-clinical neuroscience assets. The acquisition is expected to be dilutive to BMS's non-GAAP diluted earnings per share by approximately $0.30 in 2024 due to financing costs, but BMS plans to offset these costs through disciplined resource allocation and cost efficiencies. The transaction will also result in a one-time, non-deductible Acquired In-Process Research and Development charge of approximately $12 billion, impacting both GAAP and non-GAAP EPS by approximately $5.93. BMS will update its financial outlook for the first quarter of 2024 on April 25, 2024. Advisors for the transaction included Gordon Dyal & Co. and Citi for BMS, and Goldman Sachs & Co. LLC for Karuna.
2024年3月18日，百時美施貴寶（BMS）宣佈成功完成對Karuna Therapeutics, Inc. 的收購，此舉加強了百時美施貴寶（BMS）的神經科學產品組合。此次收購使Karuna成爲BMS的全資子公司，Karuna的普通股停止在納斯達克交易。該交易涉及將每股Karuna股份轉換爲獲得330.00美元現金的權利。BMS的收購包括KarXT，這是一種潛在的首創精神分裂症治療藥物，PDUFA的日期定爲2024年9月26日，以及一系列早期和臨床前神經科學資產。由於融資成本，預計此次收購將在2024年使BMS的非公認會計准則攤薄每股收益約0.30美元，但BMS計劃通過嚴格的資源配置和成本效...展開全部
2024年3月18日，百時美施貴寶（BMS）宣佈成功完成對Karuna Therapeutics, Inc. 的收購，此舉加強了百時美施貴寶（BMS）的神經科學產品組合。此次收購使Karuna成爲BMS的全資子公司，Karuna的普通股停止在納斯達克交易。該交易涉及將每股Karuna股份轉換爲獲得330.00美元現金的權利。BMS的收購包括KarXT，這是一種潛在的首創精神分裂症治療藥物，PDUFA的日期定爲2024年9月26日，以及一系列早期和臨床前神經科學資產。由於融資成本，預計此次收購將在2024年使BMS的非公認會計准則攤薄每股收益約0.30美元，但BMS計劃通過嚴格的資源配置和成本效率來抵消這些成本。該交易還將產生約120億美元的一次性、不可扣除的收購在制研發費用，對GAAP和非GAAP每股收益產生約5.93美元的影響。BMS將於2024年4月25日更新其2024年第一季度的財務展望。該交易的顧問包括BMS的戈登·戴爾公司和花旗銀行以及高盛公司。卡魯納有限責任公司。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。